Eileen Kathryn Clancy is a prominent inventor based in San Francisco, CA. She has made significant contributions to the field of biotechnology, particularly in the area of membrane fusion technologies. With a total of 3 patents to her name, her work has the potential to impact various applications in medicine and bioengineering.

Latest Patents

One of her latest patents is focused on recombinant polypeptides for facilitating membrane fusion. This invention discloses a recombinant polypeptide that has a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein. It also includes a functional myristoylation motif, a transmembrane domain from a FAST protein, and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to this recombinant polypeptide for selective fusion. The polypeptide can be incorporated into the membrane of a liposome to facilitate the delivery of bioactive compounds, such as siRNA. Alternatively, it can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.

Career Highlights

Eileen Kathryn Clancy is currently associated with Entos Pharmaceuticals Inc., where she continues to innovate and develop new technologies. Her work is characterized by a strong focus on practical applications that can enhance therapeutic delivery systems.

Collaborations

Throughout her career, Eileen has collaborated with notable professionals in her field, including John Lewis and Rae-Lynn Nesbitt. These collaborations have further enriched her research and development efforts.

Conclusion

Eileen Kathryn Clancy is a trailblazer in the field of membrane fusion technologies, with a strong portfolio of patents that showcase her innovative spirit. Her contributions are paving the way for advancements in biotechnology and therapeutic applications.